{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:16:05Z","timestamp":1790388965426,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Myocardial infarction (MI) results in loss of cardiomyocytes leading to heart failure. Despite advancements in pharmacotherapy and interventions such as revascularization, ischemic heart failure remains a challenge. Recent advancements in stem cell therapies, genetic engineering and bioengineering have shown to improve cardiac function and quality of life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methodology<\/jats:title>\n            <jats:p>Following PRISMA guidelines, randomized controlled trials clinical trials from last 12 years were systematically reviewed. All the patients included in these studies had ischemic heart failure and were subjected to different types of stem cell therapies. Protocol for this meta-analysis is registered on PROSPERO (Registration no: CRD42023399263). Data extraction and Quality assessment was done according to Cochrane handbook of systematic reviews and meta-analysis. Meta-analysis was conducted using Revman, and a random-effect model was used to calculate weighted mean differences (WMD) in left ventricular ejection fraction (LVEF), scar size and Minnesota Living with Heart Failure score (MLHFQ) pre- and post-intervention.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The pooled mean difference (MD) for scar size reduction at 6 months follow-up was \u2212\u20090.36; (95%CI [-0.63, -0.10]), I<jats:sup>2<\/jats:sup>\u2009=\u200971% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and at 12 months follow-up was \u2212\u20090.62; (95%CI [-1.03, -0.21]), I<jats:sup>2<\/jats:sup>\u2009=\u200978% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) with a positive effect direction. Weight of the studies ranged from 5.4 to 10.8% and 9.6\u201314.1% at 6 months and 12 months follow-up respectively. The pooled data analysis at 6 months and 12 months follow-up revealed weighted mean difference 0.44; (95% CI [0.13\u20130.75]), I<jats:sup>2<\/jats:sup>\u2009=\u200985% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.00001) and 0.64; 95% CI [0.14\u20131.14], I<jats:sup>2<\/jats:sup>\u2009=\u200985% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.00001) respectively. For MHLFQ score pooled weighted mean difference was calculated for 286 patients which revealed mean difference \u2212\u20090.38, (95% CI [-0.71-0.05]) (<jats:italic>p<\/jats:italic>\u2009=\u20090.02), I<jats:sup>2<\/jats:sup>\u2009=\u200969% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.002). Sensitivity analysis by excluding \u2018Gujjaro et al. 2016\u2019 revealed weighted mean difference \u2212\u20090.49; (95% CI [-0.74-0.25]) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), I<jats:sup>2<\/jats:sup>\u2009=\u200972% (<jats:italic>p<\/jats:italic>\u2009=\u20090.09).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our meta-analysis not only demonstrated consistent improvements in LVEF and reductions in scar size but also improvement in quality of life with stem cell therapies, however, the heterogeneity among studies calls for a need of standardized protocols and further research in optimizing these therapies to improve cardiomyocyte regeneration and overall cardiac repair.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13287-025-04357-8","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:42:26Z","timestamp":1756809746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiomyocyte regeneration therapy and its effect on LVEF and scar size- a systematic review and meta-analysis"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2864-1495","authenticated-orcid":false,"given":"Mahnoor","family":"Mahnoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Irtaza","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Bakhtiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salal","family":"Sharjeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roha","family":"Daneyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"issue":"5","key":"4357_CR1","first-page":"524","volume":"5","author":"GA Roth","year":"2020","unstructured":"Roth GA. Global burden of cardiovascular diseases and risk factors, 1990\u20132019. JAMA Cardiol. 2020;5(5):524\u201348.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"4357_CR2","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1161\/01.CIR.81.4.1161","volume":"81","author":"MA Pfeffer","year":"1990","unstructured":"Pfeffer MA. Ventricular remodeling after myocardial infarction. Circulation. 1990;81(4):1161\u201372.","journal-title":"Circulation"},{"issue":"9970","key":"4357_CR3","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/S0140-6736(14)61889-4","volume":"385","author":"E Braunwald","year":"2015","unstructured":"Braunwald E. The war against heart failure: the lancet lecture. Lancet. 2015;385(9970):812\u201324.","journal-title":"Lancet"},{"issue":"6","key":"4357_CR4","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/ijms20061420","volume":"20","author":"B Wernly","year":"2019","unstructured":"Wernly B. Regenerative cardiovascular therapies: stem cells and beyond. Int J Mol Sci. 2019;20(6):1420.","journal-title":"Int J Mol Sci"},{"issue":"7504","key":"4357_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nature13233","volume":"510","author":"JJH Chong","year":"2014","unstructured":"Chong JJH, Yang X, Don CW, et al. Human embryonic stem cell-derived cardiomyocytes regenerate non-human primate hearts. Nature. 2014;510(7504):273\u20137.","journal-title":"Nature"},{"issue":"12","key":"4357_CR6","first-page":"CD007888","volume":"2016","author":"SA Fisher","year":"2016","unstructured":"Fisher SA, Doree C, Mathur A, et al. Stem cell therapy for chronic ischemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 2016;2016(12):CD007888.","journal-title":"Cochrane Database Syst Rev"},{"key":"4357_CR7","doi-asserted-by":"publisher","unstructured":"Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow,C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville,J., Grimshaw, J. M., Hr\u00f3bjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson,E., McDonald, S.,\u2026 Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. The BMJ, 372. https:\/\/doi.org\/10.1136\/BMJ.N71.","DOI":"10.1136\/BMJ.N71"},{"key":"4357_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12955-016-0425-7","volume":"14","author":"A Bilbao","year":"2016","unstructured":"Bilbao A, Escobar A, Garc\u00eda-Perez L, Navarro G, Quir\u00f3s R. The Minnesota living with heart failure questionnaire: comparison of different factor structures. Health Qual Life Outcomes. 2016;14:23. https:\/\/doi.org\/10.1186\/s12955-016-0425-7. PMID: 26887590; PMCID: PMC4756518.","journal-title":"Health Qual Life Outcomes"},{"key":"4357_CR9","unstructured":"Risk of bias tools - Current version of RoB 2. (n.d.). Retrieved April 9, 2023, from https:\/\/sites.google.com\/site\/riskofbiastool\/welcome\/rob-2-0-tool\/current-version-of-rob-2"},{"issue":"1","key":"4357_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13287-024-03864-4","volume":"15","author":"FA Atewologun","year":"2024","unstructured":"Atewologun FA, Okesanya OJ, Okon II, Kayode HH, Ukoaka BM, Olaleke NO, Ogaya JB, Okikiola LA, Manirambona E, Lucero-Prisno Iii DE. Examining the potentials of stem cell therapy in reducing the burden of selected non-communicable diseases in Africa. Stem Cell Res Ther. 2024;15(1):253. https:\/\/doi.org\/10.1186\/s13287-024-03864-4.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"4357_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12265-016-9686-0","volume":"9","author":"K Anastasiadis","year":"2016","unstructured":"Anastasiadis K, et al. Implantation of a novel allogeneic mesenchymal precursor cell type in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting: an open label phase IIa trial. J Cardiovasc Translational Res Vol. 2016;9(3):202\u201313. https:\/\/doi.org\/10.1007\/s12265-016-9686-0.","journal-title":"J Cardiovasc Translational Res Vol"},{"issue":"11 Suppl 1","key":"4357_CR12","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1161\/CIRCULATIONAHA.112.092627","volume":"126","author":"AR Chugh","year":"2012","unstructured":"Chugh AR, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation Vol. 2012;126(11 Suppl 1):S54\u201364. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.092627.","journal-title":"Circulation Vol"},{"issue":"1","key":"4357_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/ejhf.700","volume":"19","author":"A Gwizdala","year":"2017","unstructured":"Gwizdala A, et al. Safety, feasibility and effectiveness of first in-human administration of muscle-derived stem\/progenitor cells modified with connexin-43 gene for treatment of advanced chronic heart failure. Eur J Heart Fail Vol. 2017;19(1):148\u201357. https:\/\/doi.org\/10.1002\/ejhf.700.","journal-title":"Eur J Heart Fail Vol"},{"issue":"9853","key":"4357_CR14","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(12)60195-0","volume":"380","author":"P Strazzullo","year":"2012","unstructured":"Strazzullo P, D\u2019Elia L, Kandala N-B, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: Meta-analysis of prospective studies. Lancet. 2012;380(9853):1629\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(12)60195-0.","journal-title":"Lancet"},{"issue":"22","key":"4357_CR15","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/j.jacc.2013.07.045","volume":"62","author":"PK Whelton","year":"2013","unstructured":"Whelton PK, Appel LJ, Sacco RL, Anderson CAM, Antman EM, Campbell N, Dunbar SB, Frohlich ED, Hall JE, Jessup M, Labarthe DR, MacGregor GA, Sacks FM, Stamler J, Vafiadis DK, Van Horn LV. Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American heart association sodium reduction recommendations. J Am Coll Cardiol. 2013;62(22):2039\u201349. https:\/\/doi.org\/10.1016\/j.jacc.2013.07.045.","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"4357_CR16","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1093\/eurheartj\/ehaa541","volume":"41","author":"RR Makkar","year":"2020","unstructured":"Makkar RR, et al. Intracoronary allogeneic heart stem cells to achieve myocardial regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. Eur Heart J Vol. 2020;41(36):3451\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa541.","journal-title":"Eur Heart J Vol"},{"key":"4357_CR17","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ijcard.2016.07.028","volume":"221","author":"A Bellavia","year":"2016","unstructured":"Bellavia A, Stilling F, Wolk A. High red meat intake and all-cause cardiovascular and cancer mortality: is the risk modified by fruit and vegetable intake? Int J Cardiol. 2016;221:270\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2016.07.028.","journal-title":"Int J Cardiol"},{"issue":"1","key":"4357_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3346\/jkms.2014.29.1.23","volume":"29","author":"JW - Lee","year":"2014","unstructured":"Lee JW, Lee SH, Youn YJ, Ahn MS, Kim JY, Yoo BS, Yoon J, Kwon W, Hong IS, Lee K, Kwan J, Park KS, Choi D, Jang YS, Hong MK. A randomized, Open-Label, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction. J Korean Med Sci. 2014;29(1):23\u201331. https:\/\/doi.org\/10.3346\/jkms.2014.29.1.23.","journal-title":"J Korean Med Sci"},{"key":"4357_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/ejhf.2178","volume":"23","author":"R Bolli","year":"2021","unstructured":"Bolli R, Mitrani RD, Hare JM, Pepine CJ, Perin EC, Willerson JT, Traverse JH, Henry TD, Yang PC, Murphy MP, March KL, Schulman IH, Ikram S, Lee DP, O\u2019Brien C, Lima JA, Ostovaneh MR, Ambale-Venkatesh B, Lewis G, Khan A, Bacallao K, Valasaki K, Longsomboon B, Gee AP, Richman S, Taylor DA, Lai D, Sayre SL, Bettencourt J, Vojvodic RW, Cohen ML, Simpson L, Aguilar D, Loghin C, Moy\u00e9 L, Ebert RF, Davis BR, Simari RD and. A phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. Eur J Heart Fail. 2021;23:661\u201374. https:\/\/doi.org\/10.1002\/ejhf.2178.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"4357_CR20","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.jtcvs.2016.07.067","volume":"152","author":"T Kaneko","year":"2016","unstructured":"Kaneko T, Loberman D, Gosev I, Rassam F, McGurk S, Leacche M, Cohn LH. Outcomes of reoperative aortic valve replacement after previous sternotomy. J Thorac Cardiovasc Surg. 2016;152(6):1521\u20137. https:\/\/doi.org\/10.1016\/j.jtcvs.2016.07.067.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"4357_CR21","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1161\/CIRCRESAHA.116.308639","volume":"119","author":"NR - Cook","year":"2016","unstructured":"Cook NR, Appel LJ, Whelton PK. Sodium intake and all-cause mortality over 20 years in the trials of hypertension prevention. Circul Res. 2016;119(5):664\u201371. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308639.","journal-title":"Circul Res"},{"issue":"2","key":"4357_CR22","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/ehf2.14281","volume":"10","author":"AA Qayyum","year":"2023","unstructured":"Qayyum AA, et al. Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure. ESC Heart Fail Vol. 2023;10(2):1170\u201383. https:\/\/doi.org\/10.1002\/ehf2.14281.","journal-title":"ESC Heart Fail Vol"},{"issue":"4","key":"4357_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/ejhf.2772","volume":"25","author":"AA Qayyum","year":"2023","unstructured":"Qayyum AA, et al. Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction - the SCIENCE trial. Eur J Heart Fail Vol. 2023;25(4):576\u201387. https:\/\/doi.org\/10.1002\/ejhf.2772.","journal-title":"Eur J Heart Fail Vol"},{"issue":"5","key":"4357_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.ahj.2014.07.017","volume":"168","author":"N Graudal","year":"2014","unstructured":"Graudal N, Hubeck-Graudal T, J\u00fcrgens G. Sodium intake and cardiovascular health: lack of definitive evidence for very low sodium intake. Am Heart J. 2014;168(5):637\u201344. https:\/\/doi.org\/10.1016\/j.ahj.2014.07.017.","journal-title":"Am Heart J"},{"key":"4357_CR25","doi-asserted-by":"publisher","unstructured":"Meta-Analysis of Cell Therapy Trials for Patients. With Heart Failure https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.304386","DOI":"10.1161\/CIRCRESAHA.116.304386"},{"key":"4357_CR26","doi-asserted-by":"publisher","unstructured":"Assmus B, Sch\u00e4chinger V, Teupe C, Britten M, Lehmann R, D\u00f6bert N, Gr\u00fcnwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106(24):3009-17. https:\/\/doi.org\/10.1161\/01.cir.0000043246.74879.cd. PMID: 12473544.","DOI":"10.1161\/01.cir.0000043246.74879.cd"},{"key":"4357_CR27","doi-asserted-by":"publisher","unstructured":"Roberto Bolli M, Solankhi X-L, Tang A, Kahlon. Cell therapy in patients with heart failure: a comprehensive review and emerging concepts. Cardiovascular Res. March 2022;118:951\u201376. https:\/\/doi.org\/10.1093\/cvr\/cvab135.","DOI":"10.1093\/cvr\/cvab135"},{"issue":"23","key":"4357_CR28","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1093\/eurheartj\/ehl388","volume":"27","author":"V Sch\u00e4chinger","year":"2006","unstructured":"Sch\u00e4chinger V, Erbs S, Els\u00e4sser A, Haberbosch W, Hambrecht R, H\u00f6lschermann H, Yu J, Corti R, Mathey DG, Hamm CW, S\u00fcselbeck T, Werner N, Haase J, Neuzner J, Germing A, Mark B, Assmus B, Tonn T, Dimmeler S, Zeiher AM. REPAIR-AMI investigators. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J. 2006;27(23):2775\u201383. https:\/\/doi.org\/10.1093\/eurheartj\/ehl388. Epub 2006 Nov 10. PMID: 17098754.","journal-title":"Eur Heart J"},{"issue":"10","key":"4357_CR29","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1161\/CIRCULATIONAHA.105.575118","volume":"113","author":"GP Meyer","year":"2006","unstructured":"Meyer GP, Wollert KC, Lotz J, Steffens J, Lippolt P, Fichtner S, Hecker H, Schaefer A, Arseniev L, Hertenstein B, Ganser A, Drexler H. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months\u2019 follow-up data from the randomized, controlled BOOST (BOne marrow transfer to enhance ST-elevation infarct regeneration) trial. Circulation. 2006;113(10):1287\u201394. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.575118. Epub 2006 Mar 6. PMID: 16520413.","journal-title":"Circulation"},{"key":"4357_CR30","doi-asserted-by":"publisher","unstructured":"Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Gr\u00f8gaard HK, Bj\u00f8rnerheim R, Brekke M, M\u00fcller C, Hopp E, Ragnarsson A, Brinchmann JE, Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006;355(12):1199\u2013\u2009209. https:\/\/doi.org\/10.1056\/NEJMoa055706. PMID: 16990383.","DOI":"10.1056\/NEJMoa055706"},{"issue":"14","key":"4357_CR31","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/eurheartj\/ehq449","volume":"32","author":"A Hirsch","year":"2011","unstructured":"Hirsch A, Nijveldt R, van der Vleuten PA, Tijssen JG, van der Giessen WJ, Tio RA, Waltenberger J, ten Berg JM, Doevendans PA, Aengevaeren WR, Zwaginga JJ, Biemond BJ, van Rossum AC, Piek JJ. Zijlstra F;HEBE investigators. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. Eur Heart J. 2011;32(14):1736\u201347. https:\/\/doi.org\/10.1093\/eurheartj\/ehq449. Epub 2010 Dec 10. PMID: 21148540.","journal-title":"Eur Heart J"},{"issue":"3","key":"4357_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1161\/CIRCULATIONAHA.119.045566","volume":"142","author":"L He","year":"2020","unstructured":"He L, Nguyen NB, Ardehali R, Zhou B. Heart regeneration by endogenous stem cells and cardiomyocyte proliferation: controversy, fallacy, and progress. Circulation. 2020;142(3):275\u201391. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.045566. Epub 2020 Jul 20. PMID: 32687441; PMCID: PMC7374760.","journal-title":"Circulation"},{"issue":"8","key":"4357_CR33","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1161\/CIRCRESAHA.111.243147","volume":"109","author":"AR -Williams","year":"2011","unstructured":"-Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011;109(8):923\u201340. https:\/\/doi.org\/10.1161\/CIRCRESAHA.111.243147. PMID: 21960725; PMCID: PMC3604746.","journal-title":"Circ Res"},{"key":"4357_CR34","doi-asserted-by":"publisher","first-page":"e934660","DOI":"10.12659\/MSM.934660","volume":"28","author":"Z Leng","year":"2022","unstructured":"Leng Z, Li L, Zhou X, Dong G, Chen S, Shang G, Kou H, Yang B, Liu H. Novel insights into the stemness and immune privilege of mesenchymal stem cells from human wharton jelly by Single-Cell RNA sequencing. Med Sci Monit. 2022;28:e934660. https:\/\/doi.org\/10.12659\/MSM.934660. PMID: 35153292; PMCID: PMC8855628.","journal-title":"Med Sci Monit"},{"issue":"33","key":"4357_CR35","doi-asserted-by":"publisher","first-page":"14022","DOI":"10.1073\/pnas.0903201106","volume":"106","author":"HC Quevedo","year":"2009","unstructured":"Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, Rodriguez JE, Valdes D, Pattany PM, Zambrano JP, Hu Q, McNiece I, Heldman AW, Hare JM. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A. 2009;106(33):14022\u20137. https:\/\/doi.org\/10.1073\/pnas.0903201106. Epub 2009 Aug 5. PMID: 19666564; PMCID: PMC2729013.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"4357_CR36","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1161\/CIRCRESAHA.114.302854","volume":"114","author":"VY Suncion","year":"2014","unstructured":"Suncion VY, Ghersin E, Fishman JE, Zambrano JP, Karantalis V, Mandel N, Nelson KH, Gerstenblith G, DiFede Velazquez DL, Breton E, Sitammagari K, Schulman IH, Taldone SN, Williams AR, Sanina C, Johnston PV, Brinker J, Altman P, Mushtaq M, Trachtenberg B, Mendizabal AM, Tracy M, Da Silva J, McNiece IK, Lardo AC, George RT, Hare JM, Heldman AW. Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally? An analysis from the percutaneous stem cell injection delivery effects on neomyogenesis (POSEIDON) randomized trial. Circ Res. 2014;114(8):1292\u2013301. Epub 2014 Jan 21. PMID: 24449819; PMCID: PMC4067050.","journal-title":"Circ Res"},{"issue":"8","key":"4357_CR37","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.116.304346","volume":"116","author":"M Gy\u00f6ngy\u00f6si","year":"2015","unstructured":"Gy\u00f6ngy\u00f6si M, Wojakowski W, Lemarchand P, Lunde K, Tendera M, Bartunek J, Marban E, Assmus B, Henry TD, Traverse JH, Moy\u00e9 LA, S\u00fcrder D, Corti R, Huikuri H, Miettinen J, W\u00f6hrle J, Obradovic S, Roncalli J, Malliaras K, Pokushalov E, Romanov A, Kastrup J, Bergmann MW, Atsma DE, Diederichsen A, Edes I, Benedek I, Benedek T, Pejkov H, Nyolczas N, Pavo N, Bergler-Klein J, Pavo IJ, Sylven C, Berti S, Navarese EP, Maurer G. ACCRUE investigators. Meta-Analysis of Cell-based cardiac studies (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015;116(8):1346\u201360. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.304346. Epub 2015 Feb 19. PMID: 25700037; PMCID: PMC4509791.","journal-title":"Circ Res"},{"issue":"6","key":"4357_CR38","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1161\/CIRCRESAHA.114.304792","volume":"117","author":"MR Afzal","year":"2015","unstructured":"Afzal MR, Samanta A, Shah ZI, Jeevanantham V, Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials. Circ Res. 2015;117(6):558\u201375. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.304792. Epub 2015 Jul 9. PMID: 26160853; PMCID: PMC4553075.","journal-title":"Circ Res"},{"issue":"9","key":"4357_CR39","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/eurheartj\/ehw543","volume":"38","author":"J Bartunek","year":"2017","unstructured":"Bartunek J, et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J Vol. 2017;38(9):648\u201360. https:\/\/doi.org\/10.1093\/eurheartj\/ehw543.","journal-title":"Eur Heart J Vol"},{"key":"4357_CR40","doi-asserted-by":"publisher","unstructured":"Bartunek J et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 61,23 (2013): 2329\u201338. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.071","DOI":"10.1016\/j.jacc.2013.02.071"},{"key":"4357_CR41","doi-asserted-by":"publisher","unstructured":"State-of-play for cellular therapies in cardiac repair and regeneration; https:\/\/doi.org\/10.1002\/stem.3446","DOI":"10.1002\/stem.3446"},{"key":"4357_CR42","doi-asserted-by":"publisher","unstructured":"Induced Pluripotent Stem Cell-Derived cardiomyocytes therapy for ischemic heart disease in animal model: A Meta-Analysis. Int J Mol Sci 2024, 25(2), 987; https:\/\/doi.org\/10.3390\/ijms25020987","DOI":"10.3390\/ijms25020987"},{"key":"4357_CR43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41536-024-00357-z","volume":"9","author":"BM Baccouche","year":"2024","unstructured":"Baccouche BM, Elde S, Wang H, et al. Structural, angiogenic, and immune responses influencing myocardial regeneration: a glimpse into the crucible. Npj Regen Med. 2024;9:18. https:\/\/doi.org\/10.1038\/s41536-024-00357-z.","journal-title":"Npj Regen Med"},{"key":"4357_CR44","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.7150\/thno.32734","volume":"9","author":"J Li","year":"2019","unstructured":"Li J, et al. Regulatory T-cells regulate neonatal heart regeneration by potentiating cardiomyocyte proliferation in a paracrine manner. Theranostics Vol. 2019;9:15 4324\u201341. https:\/\/doi.org\/10.7150\/thno.32734. 9 Jun.","journal-title":"Theranostics Vol"},{"issue":"5","key":"4357_CR45","first-page":"694","volume":"28","author":"Y Wu","year":"2021","unstructured":"Wu Y, et al. CRISPR-Cas9-based gene editing for cardiac regeneration. Cell Stem Cell. 2021;28(5):694\u2013705.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"4357_CR46","first-page":"389","volume":"25","author":"R Lai","year":"2019","unstructured":"Lai R, et al. Tissue engineering and stem cell-based cardiac repair strategies. Tissue Eng Part B Rev. 2019;25(5):389\u2013402.","journal-title":"Tissue Eng Part B Rev"},{"issue":"6","key":"4357_CR47","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1161\/CIRCRESAHA.113.300219","volume":"113","author":"SK Sanganalmath","year":"2013","unstructured":"Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview. Circ Res. 2013;113(6):810\u201334.","journal-title":"Circ Res"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04357-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-025-04357-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04357-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:24:12Z","timestamp":1757478252000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-025-04357-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4357"],"URL":"https:\/\/doi.org\/10.1186\/s13287-025-04357-8","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required as it was a systematic review and meta-analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"485"}}